Sarka Svobodova1, Radek Kucera2, Ondrej Fiala3,4, Marie Karlikova1, Andrea Narsanska5, Ilona Zedníková5, Vladislav Treska5, David Slouka1, Milena Rousarova1, Ondrej Topolcan1, Jindrich Finek3. 1. Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 2. Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic kucerar@fnplzen.cz. 3. Department of Oncology and Radiotherapy, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 4. Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 5. Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Abstract
AIM: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancer patients, when the measurement of biomarkers is performed within 6 months after surgery. PATIENTS AND METHODS: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery. Disease recurrence was recorded between 7-12 months after surgery. Disease recurrence occurred in 60 patients, while 412 patients remained in recurrence-free status. RESULTS: TPS levels of the recurrence group differed statistically significantly in the first and sixth month after surgery compared to recurrence-free group (p=0.0339, AUC=0.6056; p<0.0001, AUC=0.7196). CEA and CA 15-3 measurements did not achieve a statistically significant difference for any month examined. CONCLUSION: TPS level in the sixth month after surgery is the best candidate biomarker to predict disease recurrence. Copyright
AIM: The aim of this study was to evaluate the ability of tissue polypeptide-specific antigen (TPS), carcinoembryonic antigen (CEA), and cancer antigen 15-3 (CA 15-3) to predict relapse in breast cancerpatients, when the measurement of biomarkers is performed within 6 months after surgery. PATIENTS AND METHODS: Four hundred and seventy-two patients with breast cancer were evaluated. TPS, CEA, and CA 15-3 were measured in months 1, 3, and 6, after surgery. Disease recurrence was recorded between 7-12 months after surgery. Disease recurrence occurred in 60 patients, while 412 patients remained in recurrence-free status. RESULTS: TPS levels of the recurrence group differed statistically significantly in the first and sixth month after surgery compared to recurrence-free group (p=0.0339, AUC=0.6056; p<0.0001, AUC=0.7196). CEA and CA 15-3 measurements did not achieve a statistically significant difference for any month examined. CONCLUSION: TPS level in the sixth month after surgery is the best candidate biomarker to predict disease recurrence. Copyright
Authors: Sarah A Aglan; Mohamed Elsammak; Omar Elsammak; Eman A El-Bakoury; Heba G Elsheredy; Yasser S Ahmed; Mohamed H Sultan; Ahmed M Awad Journal: J Med Biochem Date: 2021-01-26 Impact factor: 3.402